The global panuveitis treatment market achieved a significant value of USD 3.76 billion in 2022 and is projected to reach approximately USD 8.9 billion by 2033, representing a robust CAGR of 9.5% during the forecast period from 2023 to 2033. This growth can be attributed to several factors, including the increasing prevalence of uveitis, heightened awareness of the condition, and the expanding geriatric population worldwide.
Panuveitis, a type of uveitis affecting all layers of the uveal tract, poses significant challenges for patients, often leading to severe complications if left untreated. The rising incidence of uveitis is prompting healthcare providers to seek effective treatment options, further driving market growth. Additionally, efforts to increase public awareness and education about panuveitis are contributing to early diagnosis and timely intervention.
The geriatric population, which is more susceptible to ocular conditions, is also playing a crucial role in the expansion of the panuveitis treatment market. As this demographic continues to grow, the demand for innovative treatment solutions is expected to rise correspondingly.
The panuveitis treatment market exhibited a CAGR of 4.7% during the historical period from 2018 to 2022, indicating a steady upward trend that underscores the ongoing need for effective therapies in this field. As research and development efforts continue to advance, the market is well-positioned for significant growth in the coming years, reflecting a commitment to improving patient outcomes and enhancing the quality of care for individuals affected by this condition.
2018 to 2022 Panuveitis Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Panuveitis treatment reflected a value CAGR of 4.7% during the historical period, 2018 to 2022.
The panuveitis treatment market is expected to have experienced moderate growth during this period, driven by an increasing prevalence of uveitis and a rise in the geriatric population worldwide. Advances in technology and the introduction of new therapies may have also contributed to market growth.
The market for panuveitis treatment is expected to grow in the coming years, driven by an increasing number of clinical trials for new treatments and the introduction of advanced therapies. Thus, the market for Panuveitis treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.
Market Competition
Key players in the Panuveitis treatment Market are Allergan, Inc., Novartis AG, Bausch Health Inc., AbbVie Inc., Tarsier Pharma, EyeGate Pharmaceuticals, Inc., Alimera Science Inc., Eyepoint Pharmaceutical, Santen Pharmaceutical
- Bausch Health Inc. has developed a drug called Uvadex (methoxsalen) for the treatment of certain forms of uveitis, including panuveitis. Uvadex is an oral medication that works by sensitizing the immune cells that cause inflammation in the eye to a type of light called ultraviolet A (UVA).
- AbbVie Inc. has developed a drug called Humira (adalimumab) for the treatment of various autoimmune and inflammatory disorders, including certain forms of uveitis, including panuveitis. Humira is a monoclonal antibody that selectively binds to a pro-inflammatory protein called tumor necrosis factor alpha (TNF-α), which is involved in the development of inflammation.
Key Companies Profiled
- Allergan, Inc.
- Novartis AG
- Bausch Health Inc.
- AbbVie Inc.
- Tarsier Pharma
- EyeGate Pharmaceuticals, Inc.
- Alimera Science Inc.
- Eyepoint Pharmaceutical
- Santen Pharmaceutical
Key Segments Profiled in the Panuveitis Treatment Industry Survey
Drug Class:
- Anti-inflammatory
- Antimicrobial Drugs
- Immunotherapy & Targeted Therapies
Route of Administration:
- Oral
- Topical
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
